References:
1. Wolf S, Barton D, Kottschade L et al. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. European journal of cancer 2008; 44 : 1507-15.
2. Seretny M, Currie GL, Sena ES et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. PAIN® 2014; 155 : 2461-70.
3. Vitale MG, Barbato C, Crispo A et al. ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-Zeolite to Prevent Chemotherapy-Induced Side Effects, in Particular, Peripheral Neuropathy. Molecules 2020; 25 : 2297.
4. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy.Journal of neurology 2002; 249 : 9-17.
5. Windebank AJ, Grisold W. Chemotherapy‐induced neuropathy.Journal of the Peripheral Nervous System 2008; 13 : 27-46.
6. Gordon-Williams R, Farquhar-Smith P. Recent advances in understanding chemotherapy-induced peripheral neuropathy. F1000Research 2020;9 .
7. Surai PF. Silymarin as a natural antioxidant: an overview of the current evidence and perspectives. Antioxidants 2015; 4 : 204-47.
8. Areti A, Yerra VG, Naidu V, Kumar A. Oxidative stress and nerve damage: role in chemotherapy induced peripheral neuropathy. Redox biology 2014; 2 : 289-95.
9. Yowtak J, Lee KY, Kim HY et al. Reactive oxygen species contribute to neuropathic pain by reducing spinal GABA release. Pain® 2011;152 : 844-52.
10. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World journal of gastroenterology: WJG 2011;17 : 2288.
11. Vargas-Mendoza N, Madrigal-Santillán E, Morales-González Á et al. Hepatoprotective effect of silymarin. World journal of hepatology2014; 6 : 144.
12. Borah A, Paul R, Choudhury S et al. Neuroprotective potential of silymarin against CNS disorders: insight into the pathways and molecular mechanisms of action. CNS neuroscience & therapeutics 2013;19 : 847-53.
13. Zi X, Feyes DK, Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clinical Cancer Research 1998; 4 : 1055-64.
14. Kang SN, Lee MH, Kim K-M et al. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C. Biochemical pharmacology 2001;61 : 1487-95.
15. Chaudhry V, Rowinsky EK, Sartorius SE et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society 1994; 35 : 304-11.
16. Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Supportive Care in Cancer2004; 12 : 619-25.
17. Savarese D. Common terminology criteria for adverse events.UpToDate Waltham, MA: UpToDate 2013.
18. Scott NW, Fayers P, Aaronson NK et al. EORTC QLQ-C30 reference values manual. 2008.
19. Hu S, Huang KM, Adams EJ et al. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clinical Cancer Research 2019;25 : 6295-301.
20. Smith EML, Pang H, Cirrincione C et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. Jama 2013; 309 : 1359-67.
21. Beijers A, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Supportive Care in Cancer 2014;22 : 1999-2007.
22. Avan R, Janbabaei G, Hendouei N et al. The effect of pregabalin and duloxetine treatment on quality of life of breast cancer patients with taxane-induced sensory neuropathy: a randomized clinical trial.Journal of research in medical sciences: the official journal of Isfahan University of Medical Sciences 2018; 23 .
23. Bahmani M, Shirzad H, Rafieian S, Rafieian-Kopaei M. Silybum marianum: beyond hepatoprotection. Journal of evidence-based complementary & alternative medicine 2015; 20 : 292-301.
24. Agarwal R, Agarwal C, Ichikawa H et al. Anticancer potential of silymarin: from bench to bed side. Anticancer research 2006;26 : 4457-98.
25. Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biological research 1994; 27 : 105-.
26. Mannelli LDC, Zanardelli M, Failli P, Ghelardini C. Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin. The Journal of Pain2012; 13 : 276-84.
27. Elyasi S, Shojaee FSR, Allahyari A, Karimi G. Topical silymarin administration for prevention of capecitabine‐induced hand–foot syndrome: A randomized, double‐blinded, placebo‐controlled clinical trial. Phytotherapy Research 2017; 31 : 1323-9.
28. Choi J-Y, Yi HG, Park C-S et al. Inhibition of oxaliplatin-induced neurotoxicity by silymarin through increased expression of brain-derived neurotrophic factor and inhibition of p38-MAPK. Molecular & Cellular Toxicology 2019; 15 : 145-52.
29. Soleimani V, Delghandi PS, Moallem SA, Karimi G. Safety and toxicity of silymarin, the major constituent of milk thistle extract: An updated review. Phytotherapy research 2019; 33 : 1627-38.
30. Campos R, Garrido A, Guerra R, Valenzuela A. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver. Planta medica 1989; 55 : 417-9.
31. Koksal E, GÜLÇİN İ, Beyza S et al. In vitro antioxidant activity of silymarin. 2009.
32. D’Amico R, Impellizzeri D, Cuzzocrea S, Di Paola R. ALIAmides Update: Palmitoylethanolamide and its formulations on management of peripheral neuropathic pain. International Journal of Molecular Sciences 2020; 21 : 5330.
33. Tsuda M. Microglia-mediated regulation of neuropathic pain: molecular and cellular mechanisms. Biological and Pharmaceutical Bulletin 2019; 42 : 1959-68.
34. Inoue K, Tsuda M. Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential. Nature Reviews Neuroscience 2018; 19 : 138.
35. Akbari Kordkheyli V, Nabipur E, Tafazoli A, Bagheri A. An overview on the effects of silibinin on different microRNAs expression in cancer.Journal of Mazandaran University of Medical Sciences 2018;28 : 213-29.
36. Delmas D, Xiao J, Vejux A, Aires V. Silymarin and cancer: A dual strategy in both in chemoprevention and chemosensitivity.Molecules 2020; 25 : 2009.
37. Jahanafrooz Z, Motamed N, Rinner B et al. Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator. Life sciences 2018;213 : 236-47.